Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | NK CAR-based therapies & future perspectives

Tobias Bexte • 31 Aug 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T NK-Cell Therapy

Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, gives an outlook on natural killer (NK) chimeric antigen receptor (CAR)-based therapies and what the future may look like. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tobias Bexte

3:33
Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells
Tobias Bexte • 25 Apr 2023
1:19
Gene editing of NKG2A to enhance NK cell cytotoxicity against multiple myeloma cells
Tobias Bexte • 16 Mar 2022
0:48
Advantages of primary NK cells for the treatment of patients with hematological malignancies
Tobias Bexte • 16 Mar 2022
0:59
Next steps for gene-edited NK cells in the treatment of hematological malignancies
Tobias Bexte • 16 Mar 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals